Akèy › Kansè poumon › Michigan › Ann Arbor
Etid klinik pou Kansè poumon nan Ann Arbor, MI
23 etid pou Kansè poumon ap chèche patisipan nan sit nan ak bò kote Ann Arbor (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · 7 mi lwen
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi lwen
- ak 4 plis
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · 7 mi lwen
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi lwen
- ak 4 plis
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Ap rekriteFaz 3
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi lwen
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · 15 mi lwen
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton · 18 mi lwen
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Ap rekriteFaz 3
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · 7 mi lwen
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi lwen
- ak 4 plis
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Ap rekriteFaz 3
- University of Michigan Rogel Cancer Center, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi lwen
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · 15 mi lwen
- ak 2 plis
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Ap rekriteFaz 3
- Trinity Health Ann Arbor Hospital, Ann Arbor
A Registry for People With Lung Cancer
Ap rekriteEtid obsèvasyon
- University of Michigan (Data Collection Only), Ann Arbor
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Ap rekriteFaz 2/3
- Local Institution - 0418, Ann Arbor
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Ap rekriteFaz 1/2
- University of Michigan Medical School Rogel Cancer Center, Ann Arbor
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 3
- University of Michigan, Ann Arbor
Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung
Ap rekriteFaz 3
- University of Michigan, Ann Arbor
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi lwen
- Chelsea Hospital, Chelsea · 15 mi lwen
- ak 3 plis
Gilteritinib for the Treatment of ALK NSCLC
Ap rekriteFaz 1
- University of Michigan Comprehensive Cancer Center, Ann Arbor
Prediction Augmented Screening Initiative
Ap rekrite
- VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · 7 mi lwen
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi lwen
- ak 4 plis
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · 7 mi lwen
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi lwen
- ak 4 plis
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2/3
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi lwen
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · 15 mi lwen
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton · 18 mi lwen
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Ap rekriteFaz 1/2
- University of Michigan, Ann Arbor
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Ap rekrite
- VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
Ap rekriteFaz 1/2
- VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients
Ap rekrite
- University of Michigan Comprehensive Cancer Center, Ann Arbor
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Ann Arbor
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Ap rekriteFaz 1/2
- University of Michigan, Ann Arbor
Etid Kansè poumon nan lòt vil
- Houston, TX78 etid
- Boston, MA62 etid
- New York City, NY60 etid
- Los Angeles, CA45 etid
- Washington, DC41 etid
- Arlington, VA41 etid
- Chicago, IL41 etid
- Nashville, TN40 etid
- Baltimore, MD40 etid
- St. Louis, MO39 etid
- Columbus, OH37 etid
- Philadelphia, PA36 etid
Lòt etid nan Ann Arbor
- Kansè pwostat27 etid
- Kansè nan tete26 etid
- Kansè Poumon ki pa ti selil26 etid
- Kansè (tout kalite)25 etid
- Kansè kolorektal23 etid
- Ensifizyans kadyak22 etid
- Leksemi mieloïd egi17 etid
- Maladi kadyovaskilè16 etid
- Kansè pankreyas14 etid
- Melanom12 etid
- Kansè renn (Kasinom selil renn)12 etid
- Karsinòm selil skuamèz tèt ak kou12 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.